Cargando…

Comprehensive analysis of DTYMK in pan-cancer and verification in lung adenocarcinoma

Previous documents have reported that the deoxythymidylate kinase (DTYMK) genes were involved in the progression of cancers. However, its significance in the analysis of pan-cancer and specific molecular mechanism were still poorly understood. In the present study, we conducted a comprehensive study...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yue, Wang, Hao, Liu, Ying, Yang, Jing, Zuo, Xiaoxiao, Dong, Meilian, Zhang, Zhigang, Shi, Yonggang, Deng, Xubin, Lv, Yaoyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583767/
https://www.ncbi.nlm.nih.gov/pubmed/36094557
http://dx.doi.org/10.1042/BSR20221170
Descripción
Sumario:Previous documents have reported that the deoxythymidylate kinase (DTYMK) genes were involved in the progression of cancers. However, its significance in the analysis of pan-cancer and specific molecular mechanism were still poorly understood. In the present study, we conducted a comprehensive study of the DTYMK gene associated with its clinical relevance across a broad-spectrum of human tumors. In addition, association among DTYMK gene and tumor immunogenic features was also explored. Considering the results of pan-cancer analysis, the specific tumor lung adenocarcinoma (LUAD) was chosen to further study the DTYMK-induced signaling pathways and intercellular communications in tumor progression. Our findings demonstrated that DTYMK may be a new biomarker for the prognosis and immunotherapy in various cancers. Importantly, DTYMK was expected to be a guiding marker gene for clinical prognosis and tumor personalized therapy in LUAD.